Why we're excited about it
Neurodegeneration is an area with huge unmet medical needs, where traditional approaches in drug discovery have all successively failed. It is therefore promising ground for new, innovative, companies with novel solutions.

For example, current cell and animal models of Alzheimer’s disease are poor – they rely upon overexpressing tau or Aβ, a situation unrepresentative of disease pathology. The use of data-driven approaches to accurately recreate Alzheimer’s pathology in vitro is a huge opportunity to increase the speed and accuracy of drug development in this area.

Another opportunity involves the brain’s immune system. There is mounting evidence that neuroinflammation can drive synaptic loss following the aggregation of protein. Predicting how this inflammatory response progresses could identify novel therapeutic targets.

Express interest
Full name
Your answer
Email
Your answer
Link to your LinkedIn profile / CV / web
Your answer
I'm interested in...
Submit
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service